July 19th and 20th, 2021

PsyTech is excited to announce its third annual summit, taking place on July 19th and 20th. This summit will be a spirited global discussion focused on today’s most impactful psychedelic treatments and their burgeoning commercial climate. Our panel and breakout discussions will dig into many of the topics we’ve tweeted, tagged and shared about this year, like ketamine-assisted therapy, microdosing, promising new innovations in developmental phases, and much more. We’re excited to host the most influential people in the psychedelic sector as they talk about today’s successes and tomorrow’s visions. Our summit will include a variety of broad panel discussions, intimate breakouts, and the opportunity to Q&A with the top researchers and business leaders in psychedelics.

This year’s summit has two levels of access.

General Admission gives you access to both content tracks on Tuesday, July 20th.

Premium gives you access to:

  • “Research Rollout”: an additional day of content on Monday, July 19th showcasing cutting-edge research
  • Three breakout sessions: up-close conversations with our panelists
  • Both content tracks on Tuesday, July 20th

Speakers

Head of Centre for Psychedelic Research
Imperial College London
Professor of Psychiatry and Behavioral Sciences
Johns Hopkins University School of Medicine
Director of the Center for Psychedelic Psychotherapy and Trauma Research
David_Nichols
Emeritus Professor
Purdue University College of Pharmacy
Rick Doblin Ph.D
Founder & Executive Director
Multidisciplinary Association for Psychedelic Studies (MAPS)
Associate Professor
Johns Hopkins University
Chair of Advisory Board with Red Light Holland Corp and Board Member with Mind Medicine Inc.
Managing Director
Cannacord Genuity
Ben_Sessa
Chief Medical Officer / Psychiatrist / Psychedelic Therapist
Awakn Life Sciences
Abid_Nazeer
Chief Medical Officer
PsyTech
Hayim Raclaw
CEO
PsyTech
Post doc Researcher
Imperial College London
Assistant Professor
University of California, Davis
Anna_Serin
Director, Listings Development Western Canada, USA
Canadian Securities Exchange
David_Erritzoe
Clinical Senior Lecturer and Consultant Psychiatrist
Imperial College London
Co-Founder
Microdosing Movement and Microdosing Support Network
Medical Director
Numinus Wellness Inc.
Mental health advanced practice clinician, racial-trauma researcher, scholar
Medical & Educational Services, LLC
Allison
CEO
Psychedelic.Support
Jeffrey_Becker
Co-founder & Chief Scientific Officer
Bexson Biomedical
Steven L Mandel
Founder & President
Ketamine Clinics Los Angeles
Managing Partner
JLS Fund
Director
Ambria Capital
President, Chief Business Officer,
and Co‑founder
COMPASS Pathways
Psychologist and research scientist
Emotion Science
Ronan_Levy
Founder and Executive Chairman
Field Trip health
Nadia
Director of Sales and Marketing
Psygen Industries Ltd.
Executive Director,
Clusterbusters, Int
CFO
PsyTech
Emmanuel
Assistant Professor of Neurology
Yale School of Medicine
Professor
LSU Health Sciences Center
Daniel Carcillo
Founder
Wesana Health
Adjunct Professor, School of Population
and Public Health
University of British Columbia

Featured Moderators/Podcasters

Founder & CEO
The Third Wave
President
Psychedelic Medicine Association
Psytech_Headshots
Ketamine Assisted Psychotherapist
Inbodied Life LCSW Inc
Anne_Philippi
CEO
The New Health Club
Joe_Moore
CEO
Psychedelics Today
Kyle_Buller
Director of Training and Clinical Education & Co-Founder
Greg Kubin
Co-Founder & Host
Business Trip & PsyMed Ventures
dustin
Managing Principal
Iter Investments
Psytech_Headshots
Managing Director, Co-Host
The Green Rush Podcast

Research Rollout Agenda
Monday, July 19th

9:55-10:00 EST

Welcome

Abid Nazeer M.D.

  PREMIUM ACCESS

9:55-10:00 EST
10:00-10:30 EST

What Octopuses and Psychedelics Teach us about the Social Brain

Gul Dolen Ph.D.

Dr. Gul Dölen, an associate professor of neuroscience at Johns Hopkins University, will discuss recent evidence from her lab that MDMA targets an evolutionarily ancient mechanism shared with none other than the octopus. This treatment may provide therapeutic effects by facilitating the reprogramming of certain brain processes that can often become rigid. Building on this discovery, Dr. Dölen initiated the PHATHOM project which aims to test it and related hypotheses.

 

  PREMIUM ACCESS

10:00-10:30 EST
10:30-10:45 EST

Live Q&A with Gul Dolen

  PREMIUM ACCESS

10:30-10:45 EST
10:45-11:15 EST

Effects of Psilocybin in Headache Disorders

Emmanuelle Schindler MD, Ph.D.

Emmanuelle Schindler, M.D., Ph.D. from the Yale School of Medicine, will discuss the first ever controlled investigation into the efficacy and safety of using psilocybin to treat headache disorders. Migraines remain a major cause of disability worldwide, and some evidence suggests that psychedelics can help treat individuals with migraine and cluster headaches, although controlled studies are lacking. In their research, Dr. Schindler and colleagues found that a low dose of psilocybin has sustained therapeutic effects for migraine headaches.

  PREMIUM ACCESS

10:45-11:15 EST
11:15-11:30 EST

Live Q&A with Emmanuelle Schindler

  PREMIUM ACCESS

11:15-11:30 EST
11:30-12:00 EST

Understanding the Expectation Effect in Microdosing; Data from a Citizen Science Method

David Erritzoe Ph.D.

Dr. David Erritzoe of Imperial College London will give an introduction to the science of microdosing, share early evidence related to the effects of the practice, and present data from a recent study with which he was involved: the Imperial-Beckley ‘self-blinding’ placebo study. This study is the largest placebo-controlled trial on psychedelics to date, with 191 participants.

  PREMIUM ACCESS

11:30-12:00 EST
12:00-12:15 EST

Live Q&A with David Erritzoe

  PREMIUM ACCESS

12:00-12:15 EST
12:30-1:00 EST

Psychedelics as Powerful Anti-Inflammatory Therapeutics

Charles Nichols Ph.D.

Growing research points to inflammation in the body as being associated with both physical and mental illness. In this talk, Charles Nichols Ph.D. will discuss his research including the interesting finding that psychedelics seem to be strong anti-inflammatory agents. Dr. Nichols’ data suggests that psychedelics may be able to help treat inflammatory conditions including asthma and cardiovascular disease. His lab is currently working to develop new 5-HT2A targeting drugs for use as anti-inflammatories.

  PREMIUM ACCESS

12:30-1:00 EST
1:00-1:15 EST

Live Q&A with Charles Nichols

  PREMIUM ACCESS

1:00-1:15 EST
1:20-1:50 EST

Beyond PTSD Symptom Improvement:
Effects of MDMA on Sleep, Post-traumatic Growth, and Depression

Allison Feduccia Ph.D.

MDMA-assisted therapy is under investigation as a novel treatment for post-traumatic stress disorder (PTSD). This treatment approach recently demonstrated significant PTSD symptom improvements in a Phase 3 clinical trial and received Breakthrough Therapy designation by the FDA in 2017. Secondary measures of sleep quality, depression, and post-traumatic growth provide additional evidence on the utility of MDMA-assisted therapy for treating individuals with PTSD. Determining who is unlikely to respond to this intensive drug-therapy combination is of clinical interest. This presentation will explore the possible psychological and neurological mechanisms for the robust effects of MDMA on the constellation of PTSD symptoms and other positive outcomes after treatment.

PREMIUM ACCESS

1:20-1:50 EST

Medical Track
Tuesday, JULY 20th

10:05 AM – 10:50 AM EST

The Tools and Tribulations of Ketamine

Moderated by: Lauren Taus, LCSW

10:05 AM – 10:50 AM EST
11:05 AM – 11:55 AM EST

Where Research Meets Industry

Moderated by: Joe Moore

11:05 AM – 11:55 AM EST
11:55AM – 12:25 PM EST

Individual breakout sessions with each panelist

  PREMIUM ACCESS

11:55AM – 12:25 PM EST
12:25PM – 1:10 PM EST

Psychedelics as a Destination: Can We Skip the Trip and Move Right to Healing?

Moderated by: Kyle Buller

12:25PM – 1:10 PM EST
1:10 PM – 1:40 PM EST

Premium break out session

  PREMIUM ACCESS

1:10 PM – 1:40 PM EST
1:55 PM – 2:40 PM EST

The Non-Medical Potential of Psychedelics:

Love, Creativity and Cognition

Moderated by: Anne Phillipi

1:55 PM – 2:40 PM EST
2:40 PM – 3:10 PM EST

Premium breakout session

  PREMIUM ACCESS

2:40 PM – 3:10 PM EST
3:10 PM – 3:55 PM EST

The Arrival of Psychedelics: Paving the Way to Normalization & Accessibility

Moderated by: Lynn Marie Morski, MD, JD

3:10 PM – 3:55 PM EST
3:55 PM – 4:40 PM EST

Premium breakout session

  PREMIUM ACCESS

3:55 PM – 4:40 PM EST
4:40 PM – 5:25 PM EST

Benefits of Microdosing:

Profound or Placebo?

with David Erritzoe Ph.D. and Adam Bralage

Moderated by: Paul Austin

4:40 PM – 5:25 PM EST

Business and Finance Track
Tuesday, July 20th

10:05 AM – 10:50 AM EST

Mergers, Funding, and Valuations: Analysis and Prediction in Psychedelic Markets

Moderated by: Anne Donohoe

10:05 AM – 10:50 AM EST
10:50 AM – 11:20 AM EST

Breakout session

  PREMIUM ACCESS

10:50 AM – 11:20 AM EST
Lars ronen
11:20 AM – 12:05 PM EST

Setting up Shop: Geo-opportunities and Challenges in Building a Psychedelic Company

Moderated by: Anne Donohoe

11:20 AM – 12:05 PM EST
Lars ronen
12:05 PM – 12:35 PM EST

Breakout session

  PREMIUM ACCESS

12:05 PM – 12:35 PM EST
1:50 PM – 2:35 PM EST

Across the Value Chain

with Hayim Raclaw and Nadia Van der Heyden

Moderated by: Dustin Robinson

1:50 PM – 2:35 PM EST
2:35 PM – 3:20 PM EST

Raising Early Stage Equity

Moderated by: Hayim Raclaw

2:35 PM – 3:20 PM EST
3:20 PM – 3:50 PM EST

Breakout session

  PREMIUM ACCESS

3:20 PM – 3:50 PM EST
4:05 PM – 4:50 PM EST

Pitch Event

 

4:05 PM – 4:50 PM EST
Associate Professor
Johns Hopkins University

Companies and Academic Institutions presenting at PsyTech